- LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) available for the treatment of COPD in the U.S. - MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc.

- LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S. - MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc.

U.S. Food and Drug Administration Approves Cayston(R) (Aztreonam for Inhalation Solution) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa - First ...

Please provide your email address to receive an email when new articles are posted on . Tobramycin inhalation solution was effective in lowering bacterial density and positively influenced quality of ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA ...

Perforomist is a solution formulation of the long-acting beta 2-agonist formoterol fumarate, which is administered by inhalation via nebulization. It acts as a bronchodilator by stimulating beta 2 ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 28, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that that the BREEZE study of Tyvaso DPI (inhaled ...

Perforomist (formoterol) is a brand-name drug that’s prescribed for chronic obstructive pulmonary disease (COPD) in adults. Perforomist comes as a liquid that’s inhaled with a nebulizer twice per day.

King Pharmaceuticals has decided to discontinue manufacturing Intal nebulizer solution (cromolyn sodium inhalation solution). The decision is based upon many factors, including the company’s ...